LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: 3-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 1 STUDY

被引：0

作者：

Mcinnes, I. ^{[1
]}

Kato, K. ^{[2
]}

Magrey, M. ^{[3
]}

Merola, J. F. ^{[4
,5
]}

Kishimoto, M. ^{[6
]}

Haaland, D. ^{[7
,8
]}

Li, Y. ^{[2
]}

Liu, Y. ^{[2
]}

Liu, J. ^{[2
]}

Lippe, R. ^{[9
]}

Wung, P. ^{[2
]}

机构：

[1] Univ Glasgow, Coll Med Vet & Life Sci, Glasgow, Lanark, Scotland

[2] AbbVie Inc, Immunol, N Chicago, IL USA

[3] Case Western Reserve Univ, Sch Med, Rheumatol, Cleveland, OH USA

[4] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA

[5] Harvard Med Sch, Boston, MA 02115 USA

[6] Kyorin Univ, Sch Med, Dept Nephrol & Rheumatol, Mitaka, Tokyo, Japan

[7] McMaster Univ, Hamilton, ON, Canada

[8] Waterside Clin, Barrie, ON, Canada

[9] AbbVie Deutschland GmbH & Co KG, Immunol, Wiesbaden, Germany

来源：

关键词：

Psoriatic arthritis; Safety;

D O I：

10.1136/annrheumdis-2023-eular.3116

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

POS1541

引用

页码：1137 / 1138

页数：2